drug summary · 3 NDC codes
AMJEVITA 80 mg/.8mL
adalimumab-atto
HUMAN PRESCRIPTION DRUG record from the RxAtlas dataset, marketing status BLA. Facts and NDC codes below are exported values from the current release, not inferred or edited prose.
Facts
Field definitions, types, and provenance rules are in the data dictionary.
| generic name | adalimumab-atto |
|---|---|
| active ingredients | ADALIMUMAB |
| dosage form | INJECTION |
| route | SUBCUTANEOUS |
| strength | 80 mg/.8mL |
| marketing status | BLA |
| DEA schedule | not reported |
| application number | BLA761024 |
| ATC code | not reported |
| RxCUI | not reported |
| manufacturer | Amgen, Inc |
| product type | HUMAN PRESCRIPTION DRUG |
| pharmacologic class | Antibodies; Antibodies, Monoclonal [CS]; Monoclonal [CS]; Tumor Necrosis Factor Blocker [EPC]; Tumor Necrosis Factor Receptor Blocking Activity [MoA] |
NDC codes
3 National Drug Codes are mapped to this product in the current release. Package descriptions are not part of the published export, so the NDC code is the canonical package identifier here.
| NDC | Package description |
|---|---|
| 55513-481 | — |
| 55513048101 | — |
| 55513048102 | — |
Other adalimumab-atto products
6 other products in the current release publish the same generic name. Strength, dosage form, and labeler are what distinguish them.
- AMJEVITA 10 mg/.2mLINJECTION · Amgen, Inc
- AMJEVITA 20 mg/.2mLINJECTION · Amgen, Inc
- AMJEVITA 20 mg/.4mLINJECTION · Amgen, Inc
- AMJEVITA 40 mg/.4mLINJECTION · Amgen, Inc
- AMJEVITA 40 mg/.8mLINJECTION · Amgen USA Inc.
- AMJEVITA 40 mg/.8mLINJECTION · Amgen, Inc
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access to the full catalogue; credited toward the licence.